Добавил:
kiopkiopkiop18@yandex.ru t.me/Prokururor I Вовсе не секретарь, но почту проверяю Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз: Предмет: Файл:
Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_4421_Библиотеки_им_академика_М_И_Перельмана.pdf
Скачиваний:
0
Добавлен:
30.08.2026
Размер:
63 Мб
Скачать
64
-=
==
[]
()
10
[]
() ()
[]
()
[]
()
()
()
()
R. E. Bourey
. Table 5.5 Diagnosis of hepatosteatosis (fatty liver) and steatohepatitis with brosis (cirrhosis)– see text for details
Citation Cut- off Sensitivity (%) Specicity (%)
Hepatosteatosis
Screening test
Fatty liver index (FLI) [41] 30 87 64
NAFLD liver fat score (for liver fat>5.6%) [39] -0.64 86 71
Denitive test
5
Magnetic resonance proton density fat fraction (PDFF) C.f., [42]
Steatohepatitis with brosis
Screening test
Fibrosis-4 (FIB-4) [43, 44] <1.3 85 65
Vibration controlled transient elastography in NAFLD (kPa) C.f., [45] 10.3 90 87
Denitive test
Liver biopsy
NAFLD Liver Fat Score (for liver fat dened as >5.6%) is given by the following calculation [39]:
NAFLD LFS
289118
..
-+
+
045
.yypediabetesyes /no
+[.
015
+
004094..ASTU/L AST/ALT
The FLI has the disadvantage of requirement for measure­ment of waist circumference, a potentially troublesome measurement in patients with no waist. Although the NAFLD liver fat score avoids this measurement, it relies on assessment of metabolic syndrome and accurate diagnosis of T2DM. In this calculation, the metabolic syndrome was dened according to criteria of the International Diabetes Federation [40]: central obesity (waist circum­ference 94 cm in men and 80 cm in women) and at least two of the following factors: (1) serum triglycerides 1.70mmol/L or specic treatment for this lipid abnor­mality; (2) serum high-density lipoprotein (HDL) choles­terol <1.03mmol/L in men and <1.29mmol/L in women or specic treatment for this lipid abnormality; (3) systolic blood pressure (BP) 130mm Hg or diastolic BP 85mm Hg or treatment for previously diagnosed hypertension; and (4) fasting plasma glucose 5.6mmol/L or previously diagnosed type 2 diabetes. Although the requirement to screen for components of metabolic syndrome seems to add some complexity to the calculation, data for screening should be available from standard order sets for automatic analysis within the EHR.
metabolic syndromeyes /no
t
220
fasting serum insulin mU/L
[]
()
==
]]
-
()
For validated assessment of risk for liver brosis and cirrhosis in the context of NAFLD, we recommend additional calculation of Fibrosis-4 (FIB-4) with subse­quent study by vibration-controlled transient elastogra­phy or biopsy.
Fibrosis-4 (FIB-4) is calculated by the following equation (McPherson, Stewart, Henderson, Burt, & Day, 2010; Sterling etal., 2006):
FIB
- 4
A patient with brosis in the context of hepatosteato­sis can be expected to have an element of irreversible liver dysfunction. Treatment to arrest progression and to reduce fat content of the liver should be aggressive. Anesthesiologists will need to be aware of the likelihood of cirrhosis and adjust anesthesia and perioperative protocols as needed. When in doubt, prudence dictates consultation with a hepatologist and liver biopsy to fully dene liver disease and risks.

5.6 Conclusions

5 Recognition of metabolic disease associated with
obstructive sleep apnea allows modication of ther-
apy for sleep apnea to avoid risk of injury to the
patient and to improve chances for a successful out-
come. Specic strategies for management are covered
in parts III and IV of this book.
AgeyearAST U/L
=
PLT/LALT
10 9
é
()
ë
12
ù
û
/
Diagnostic Considerations inMetabolic Disease Associated withObstructive Sleep Apnea
65
5
5 Documentation of associated disease and complex-
ity of care has fast become important to sufcient reimbursement for services.
5 Diagnosis of obesity and associated morbidities will
allow not only detection of additional metabolic dis­ease such as diabetes and fatty liver, but also requires recognition of mechanical problems such as arthritis and anatomical compromise of upper airway by adi­pose tissue, which in turn justies therapy specic to obesity.
5 Diagnosis and treatment of hypertension are impor-
tant in the design of therapeutic programs for diet and exercise, as well as reduction in perioperative risks associated with surgical therapy.
5 Recognition of prediabetes and diabetes allows reim-
bursement for treatment through multidisciplinary clinics that specically address metabolic disease, and allows more accurate calculation of cardiovas­cular risks associated with exercise or surgical inter­vention.
5 Recognition of simple hepatosteatosis allows ther-
apy aimed at reversal and prevention of steatohepa­titis, irreversible brosis, and hepatic dysfunction.
5 Recognition of steatohepatitis with brosis and cir-
rhosis allows recognition of risk for cardiovascular disease, metabolic dysfunction, coagulopathy, and thrombocytopenia, and thereby better management of perioperative risks.
5 Diagnosis and treatment of metabolic disease can be
easily addressed through efcient use of electronic health records, problem-generated order sets, and a multidisciplinary team.

References

1. St-Onge MP, Shechter A.Sleep disturbances, body fat distribu­tion, food intake and/or energy expenditure: pathophysiological aspects. Horm Mol Biol Clin Investig. 2014;17(1):29–37. https://
doi.org/10.1515/hmbci-2013-0066.
2. Depner CM, Stothard ER, Wright KP Jr. Metabolic con­sequences of sleep and circadian disorders. Curr Diab Rep. 2014;14(7):507. https://doi.org/10.1007/s11892-014-0507-z.
3. Liu A, Kushida CA, Reaven GM.Habitual shortened sleep and insulin resistance: an independent relationship in obese individu­als. Metabolism. 2013;62(11):1553–6. https://doi.org/10.1016/j.
metabol.2013.06.003.
4. Auclair A, Biertho L, Marceau S, Hould FS, Biron S, Lebel S, Julien F, Lescelleur O, Lacasse Y, Piche ME, Cianone K, Par­lee SD, Goralski K, Martin J, Bastien M, St-Pierre DH, Poirier P. Bariatric surgery-induced resolution of hypertension and obstructive sleep apnea: impact of modulation of body fat, ecto­pic fat, autonomic nervous activity, inammatory and adipokine proles. Obes Surg. 2017; https://doi.org/10.1007/s11695-017-
2737-z.
5. Rasheid S, Banasiak M, Gallagher SF, Lipska A, Kaba S, Ven­timiglia D, Anderson WM, Murr MM. Gastric bypass is an effective treatment for obstructive sleep apnea in patients with clinically signicant obesity. Obes Surg. 2003;13(1):58–61.
6. Foster GD, Borradaile KE, Sanders MH, Millman R, Zammit G, Newman AB, Wadden TA, Kelley D, Wing RR, Pi-Sunyer FX, Reboussin D, Kuna ST, Sleep ARGLARG.A randomized study on the effect of weight loss on obstructive sleep apnea among obese patients with type 2 diabetes: the Sleep AHEAD study. Arch Intern Med. 2009;169(17):1619–26. https://doi.
org/10.1001/archinternmed.2009.266.
7. Trenell MI, Ward JA, Yee BJ, Phillips CL, Kemp GJ, Grunstein RR, Thompson CH.Inuence of constant positive airway pres­sure therapy on lipid storage, muscle metabolism and insulin action in obese patients with severe obstructive sleep apnoea syndrome. Diabetes Obes Metab. 2007;9(5):679–87. https://doi.
org/10.1111/j.1463-1326.2006.00649.x.
8. Chin K, Shimizu K, Nakamura T, Narai N, Masuzaki H, Ogawa Y, Mishima M, Nakamura T, Nakao K, Ohi M.Changes in intra­abdominal visceral fat and serum leptin levels in patients with obstructive sleep apnea syndrome following nasal continuous positive airway pressure therapy. Circulation. 1999;100(7):706–12.
9. Bourey RE, Bourey JR, Habbal N, Balaa A.Early gain in body mass with continuous positive airway pressure therapy for obstructive sleep apnea (Anfängliche Gewichtszunahme bei kon­tinuierlicher Positivdruck-Therapie wegen obstruktiver Schla­fapnoe. Anfängliche Gewichtszunahme bei CPAP-Therapie). Somnologie. 2010;14(3):207–12. https://doi.org/10.1007/s11818-
010-0483-8.
10. American Medical Association (2013) H440.842 Recognition of Obesity as a Disease. Available at: https://www. amaassn. org/ssl3/
ecomm/PolicyFinderForm. pl?site=www. ama-assn. org&uri=/ resources/html/PolicyFinder/policyles/HnE/H-440. 842. HTM.
11. Garvey WT, Mechanick JI, Brett EM, Garber AJ, Hurley DL, Jastreboff AM, Nadolsky K, Pessah-Pollack R, Plodkowski R, Reviewers of the AACEOCPG.American Association of Clini­cal Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract. 2016;22(Suppl 3):1–203.
https://doi.org/10.4158/EP161365.GL.
12. Tilkian AG, Guilleminault C, Schroeder JS, Lehrman KL, Simmons FB, Dement WC. Hemodynamics in sleep-induced apnea. Studies during wakefulness and sleep. Ann Intern Med. 1976;85(6):714–9.
13. Coccagna G, Mantovani M, Brignani F, Parchi C, Lugaresi E.Continuous recording of the pulmonary and systemic arterial pressure during sleep in syndromes of hypersomnia with periodic breathing. Bull Physiopathol Respir (Nancy). 1972;8(5):1159–72.
14. Carlson JT, Hedner JA, Ejnell H, Peterson LE.High prevalence of hypertension in sleep apnea patients independent of obe­sity. Am J Respir Crit Care Med. 1994;150(1):72–7. https://doi.
org/10.1164/ajrccm.150.1.8025776.
15. Millman RP, Redline S, Carlisle CC, Assaf AR, Levinson PD. Daytime hypertension in obstructive sleep apnea. Preva­lence and contributing risk factors. Chest. 1991;99(4):861–6.
16. Levinson PD, Millman RP. Causes and consequences of blood pressure alterations in obstructive sleep apnea. Arch Intern Med. 1991;151(3):455–62.
17. Min HJ, Cho YJ, Kim CH, Kim DH, Kim HY, Choi JI, Lee JG, Park S, Cho HJ.Clinical features of obstructive sleep apnea that determine its high prevalence in resistant hypertension. Yonsei Med J. 2015;56(5):1258–65. https://doi.org/10.3349/
ymj.2015.56.5.1258.
18. Muxfeldt ES, Margallo VS, Guimaraes GM, Salles GF.Preva­lence and associated factors of obstructive sleep apnea in patients with resistant hypertension. Am J Hypertens. 2014;27(8):1069–
78. https://doi.org/10.1093/ajh/hpu023.
19. Whelton PK, Carey RM, Aronow WS, Casey DE, Jr., Collins KJ, Dennison Himmelfarb C, DePalma SM, Gidding S, Jam­erson KA, Jones DW, MacLaughlin EJ, Muntner P, Ovbiagele
66
R. E. Bourey
B, Smith SC, Jr., Spencer CC, Stafford RS, Taler SJ, Thomas RJ, Williams KA, Sr., Williamson JD, Wright JT, Jr. 2017 ACC/ AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/ PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2017.
https://doi.org/10.1161/HYP.0000000000000065.
20. Kent BD, Grote L, Ryan S, Pepin JL, Bonsignore MR, Tkacova R, Saaresranta T, Verbraecken J, Levy P, Hedner J, McNicholas WT.Diabetes mellitus prevalence and control in sleep-disordered breathing: the European Sleep Apnea Cohort (ESADA) study.
5
Chest. 2014;146(4):982–90. https://doi.org/10.1378/chest.13-2403.
21. Mahmood K, Akhter N, Eldeirawi K, Onal E, Christman JW, Carley DW, Herdegen JJ.Prevalence of type 2 diabetes in patients with obstructive sleep apnea in a multi-ethnic sample. J Clin Sleep Med. 2009;5(3):215–21.
22. Einhorn D, Stewart DA, Erman MK, Gordon N, Philis-Tsimikas A, Casal E.Prevalence of sleep apnea in a population of adults with type 2 diabetes mellitus. Endocr Pract. 2007;13(4):355–62.
https://doi.org/10.4158/EP.13.4.355.
23. Foster GD, Sanders MH, Millman R, Zammit G, Borradaile KE, Newman AB, Wadden TA, Kelley D, Wing RR, Sunyer FX, Darcey V, Kuna ST, Sleep ARG. Obstructive sleep apnea among obese patients with type 2 diabetes. Diabetes Care. 2009;32(6):1017–9. https://doi.org/10.2337/dc08-1776.
24. Amin A, Ali A, Altaf QA, Piya MK, Barnett AH, Raymond NT, Tahrani AA.Prevalence and associations of obstructive sleep apnea in South Asians and White Europeans with type 2 diabe­tes: a cross-sectional study. J Clin Sleep Med. 2017;13(4):583–9.
https://doi.org/10.5664/jcsm.6548.
25. Donovan LM, Rueschman M, Weng J, Basu N, Dudley KA, Bakker JP, Wang R, Bertisch SM, Patel SR. The effectiveness of an obstructive sleep apnea screening and treatment pro­gram in patients with type 2 diabetes. Diabetes Res Clin Pract. 2017;134:145–52. https://doi.org/10.1016/j.diabres.2017.10.013.
26. Ziegler AG, Pueger M, Winkler C, Achenbach P, Akolkar B, Krischer JP, Bonifacio E. Accelerated progression from islet autoimmunity to diabetes is causing the escalating incidence of type 1 diabetes in young children. J Autoimmun. 2011;37(1):3–7.
https://doi.org/10.1016/j.jaut.2011.02.004.
27. Verbeeten KC, Elks CE, Daneman D, Ong KK. Association between childhood obesity and subsequent Type 1 diabetes: a sys­tematic review and meta-analysis. Diabet Med. 2011;28(1):10–8.
https://doi.org/10.1111/j.1464-5491.2010.03160.x.
28. American Diabetes Association. Standards of medical care in diabetes – 2017. Diabetes Care. 2017;40(Suppl 1):S1–S135.
https://doi.org/10.2337/dc17-S001.
29. Gallagher EJ, Le Roith D, Bloomgarden Z.Review of hemoglo­bin A(1c) in the management of diabetes. J Diabetes. 2009;1(1):9–
17. https://doi.org/10.1111/j.1753-0407.2009.00009.x.
30. American Association of Clinical Endocrinologists Board of D, American College of Endocrinologists Board of T.American Association of Clinical Endocrinologists/American College of Endocrinology statement on the use of hemoglobin A1c for the diagnosis of diabetes. Endocr Pract. 2010;16(2):155–6. https://
doi.org/10.4158/EP.16.2.155.
31. Kim WR, et al. (2015) OPTN/SRTR 2015 Annual data report: liver. http://srtr. transplant. hrsa. gov/annual_reports/Default. aspx.
32. Younossi ZM, Stepanova M, Afendy M, Fang Y, Younossi Y, Mir H, Srishord M.Changes in the prevalence of the most com­mon causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol. 2011;9(6):524–30. e521; quiz e560. https://doi.org/10.1016/j.cgh.2011.03.020.
33. Benotti P, Wood GC, Argyropoulos G, Pack A, Keenan BT, Gao X, Gerhard G, Still C. The impact of obstructive sleep apnea on nonalcoholic fatty liver disease in patients with severe obesity. Obesity (Silver Spring). 2016;24(4):871–7. https://doi.
org/10.1002/oby.21409.
34. Musso G, Olivetti C, Cassader M, Gambino R. Obstructive sleep apnea-hypopnea syndrome and nonalcoholic fatty liver disease: emerging evidence and mechanisms. Semin Liver Dis. 2012;32(1):49–64. https://doi.org/10.1055/s-0032-1306426.
35. Aron-Wisnewsky J, Minville C, Tordjman J, Levy P, Bouillot JL, Basdevant A, Bedossa P, Clement K, Pepin JL.Chronic inter­mittent hypoxia is a major trigger for non-alcoholic fatty liver disease in morbid obese. J Hepatol. 2012;56(1):225–33. https://
doi.org/10.1016/j.jhep.2011.04.022.
36. Qi JC, Huang JC, Lin QC, Zhao JM, Lin X, Chen LD, Huang JF, Chen X.Relationship between obstructive sleep apnea and nonalcoholic fatty liver disease in nonobese adults. Sleep Breath. 2016;20(2):529–35. https://doi.org/10.1007/s11325-015-1232-9.
37. Ghosh S, Kaw M, Patel PR, Ledford KJ, Bowman TA, McIn­erney MF, Erickson SK, Bourey RE, Najjar SM. Mice with null mutation of Ceacam I develop nonalcoholic steatohepa­titis. Hepat Med. 2010;2010(2):69–78. https://doi.org/10.2147/
HMER.S8902.
38. Aberg F, Helenius-Hietala J, Puukka P, Farkkila M, Jula A.Interaction between alcohol consumption and metabolic syn­drome in predicting severe liver disease in the general popula­tion. Hepatology. 2017. https://doi.org/10.1002/hep.29631.
39. Kotronen A, Peltonen M, Hakkarainen A, Sevastianova K, Berg­holm R, Johansson LM, Lundbom N, Rissanen A, Ridderstrale M, Groop L, Orho-Melander M, Yki-Jarvinen H.Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors. Gastroenterology. 2009;137(3):865–72. https://
doi.org/10.1053/j.gastro.2009.06.005.
40. Alberti KG, Zimmet P, Shaw J, Group IDFETFC. The metabolic syndrome--a new worldwide denition. Lancet. 2005;366(9491):1059–62. https://doi.org/10.1016/S0140-
6736(05)67402-8.
41. Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, Tiribelli C.The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006;6:33. https://doi.org/10.1186/1471-
230X-6-33.
42. Unal E, Idilman IS, Karcaaltincaba M. Multiparametric or practical quantitative liver MRI: towards millisecond, fat frac­tion, kilopascal and function era. Expert Rev Gastroenterol Hepatol. 2017;11(2):167–82. https://doi.org/10.1080/17474124.2
017.1271710.
43. Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Mon­taner J, M SS, Torriani FJ, Dieterich DT, Thomas DL, Mess­inger D, Nelson M, Investigators AC.Development of a simple noninvasive index to predict signicant brosis in patients with HIV/HCV coinfection. Hepatology. 2006;43(6):1317–25. https://
doi.org/10.1002/hep.21178.
44. McPherson S, Stewart SF, Henderson E, Burt AD, Day CP. Simple non-invasive brosis scoring systems can reliably exclude advanced brosis in patients with non-alcoholic fatty liver disease. Gut. 2010;59(9):1265–9. https://doi.org/10.1136/
gut.2010.216077.
45. Singh S, Muir AJ, Dieterich DT, Falck-Ytter YT. American Gastroenterological Association Institute technical review on the role of elastography in chronic liver diseases. Gastroen­terology. 2017;152(6):1544–77. https://doi.org/10.1053/j.gas-
tro.2017.03.016.
67
Diagnostic Considerations for OSA
Contents
Chapter 6 Clinical Evaluation of the Obstructive Sleep Apnea
Patient–69
Raman K. Malhotra and Rocio Zeballos-Chavez
Chapter 7 Diagnostic Testing for Obstructive Sleep Apnea–75
Meghna P. Mansukhani, Bhanu Prakash Kolla, and Kannan Ramar
II
Chapter 8 Cone-Beam CT Use for Airway Imaging–85
Juan Martin Palomo, Tarek Elshebiny, and Kingman Strohl
Chapter 9 Craniofacial Morphology Related to Obstructive
Sleep Apnea: Growth of Craniofacial Bones and the Upper Airway–105
Su-JungKim andKiBeomKim
Chapter 10 Orthodontics and Sleep-Disordered Breathing–135
KiBeomKim andSu-JungKim
Chapter 11 Obstructive Sleep Apnea in the Setting of Mandibular
Condyle Resorption–165
W.JonathanFillmore
Clinical Evaluation oftheObstructive Sleep ApneaPatient
RamanK.Malhotra andRocioZeballos-Chavez
Contents
6.1 Background – 70
6.2 History Taking – 70
6.3 Physical Examination – 72
6.4 Conclusion – 72
69
6
References – 73
© Springer Nature Switzerland AG 2021 K. B. Kim et al. (eds.), Management of Obstructive Sleep Apnea, https://doi.org/10.1007/978-3-030-54146-0_6
70
R. K. Malhotra and R. Zeballos-Chavez

6.1 Background

there are other possible causes of these symptoms that can be difcult for patients or clinicians to distinguish.
Individuals with obstructive sleep apnea typically pres­ent to clinical attention with a chief complaint of exces­sive daytime sleepiness, snoring, or witnessed apneas during sleep. Excessive daytime sleepiness (EDS) is dened as the inability to stay awake and alert during the major waking episodes of the day, resulting in unin­tended lapses into drowsiness or sleep [1]. This symptom is common among the population, with estimates that more than 30% of the population in the United States has daytime sleepiness that interferes with their quality
6
of life [2]. The daytime sleepiness may affect important activities such as work or taking care of children, or may occur at times that are dangerous such as driving a vehi­cle. The best initial step in evaluation of patients with suspected obstructive sleep apnea includes a detailed history and physical examination [3].
Mood disorders, endocrinopathies, and certain rheuma­tological disorders commonly cause fatigue. Specically asking the patient if they actually doze off or fall asleep in sedentary situations versus not wanting to get up and do something active can sometimes help determine if the patient has hypersomnia from a primary sleep disor­der or fatigue from another medical cause. Of note, even with a good history, many patients with sleep disorders will still describe their sleep disorder with presenting symptoms of fatigue or lack of energy, so these symp­toms should still be taken seriously in the evaluation of sleep apnea [4]. Obstructive sleep apnea can also cause symptoms of decreased attention, cognition, and poor memory. Hyperactivity and inattention are a common presenting complaint of obstructive sleep apnea, espe­cially in children [5].
In addition to asking about sleepiness, it is essential
to investigate other common clinical symptoms of

6.2 History Taking

obstructive sleep apnea. The presence, frequency, and intensity of snoring are key features in patients with
Because many patients presenting for evaluation of obstructive sleep apnea report excessive daytime sleepi­ness, it is important to further investigate the presence and severity of excessive daytime sleepiness. Subjective scales, such as the Epworth Sleepiness Scale (See
. Fig.6.1), can quickly attempt to measure the level of
sleepiness during the day as reported by the patient. This can be further assessed (many times more effectively) by directly inquiring about different circumstances where sleepiness occurs or affects them. Providers can ask patients if they feel sleepiness affects activities such as driving, work, school, or social activities. Many times, the patient may underestimate the severity or even pres­ence of excessive daytime sleepiness. This can be due to the chronic nature of the symptoms, as it may be dif­cult for the patient to know what normal alertness dur­ing the day is supposed to be if symptoms have persisted for years. Sleepiness also affects the ability of the brain to self-assess performance, hence leading to inaccurate judgments by the patient on their ability to stay alert. It can be helpful to ask any family members, friends, or coworkers about the patient’s level of sleepiness, as they may have a different and more accurate perspective. Inquiring about when and how often daytime sleepiness occurs can also be helpful in the evaluation, especially because there are numerous causes for a presenting com­plaint of excessive daytime sleepiness that also need to be considered in the differential diagnosis (See
.
Table6.1). Insufcient sleep (getting less than 7hours
per a day on average) is the most common cause of excessive daytime sleepiness in the United States.
It can also be helpful to ask if the patient’s sleepiness
is more consistent with fatigue or decreased energy, as
obstructive sleep apnea. Snoring may not be apparent to the patient, and it is important to ask a bed partner or collateral source about the presence of snoring or noisy breathing. Patients may report that their bed partner or someone sharing a room with them notices apneas or pauses in their breathing during sleep. Other symptoms that can be attributed to obstructive sleep apnea include nighttime awakenings, night sweats, nocturia, acid reux, and morning headaches. These symptoms are noted more commonly in patients with sleep apnea, but are nonspecic and can be related to numerous other eti­ologies. Finally, many patients with obstructive sleep apnea may present with insomnia or disrupted sleep.
It is important to consider evaluation for other
causes of hypersomnia, especially because patients with obstructive sleep apnea may also have other contribut­ing sleep disorders also responsible for poor sleep qual­ity (See Table6.1). Evaluation for insufcient sleep by asking about bedtime, wake times, and sleep schedules is essential. Adults require at least seven hours of sleep for optimal health, and insufcient sleep is the most com­mon causes of sleepiness [6]. Restless legs syndrome can be a cause of excessive daytime sleepiness by causing nighttime sleep disruption. This diagnosis can be evalu­ated by asking the patient about extremity discomfort or an urge to move their legs that is worse at night. The symptoms improve with movement and cause disrup­tion of their sleep. Though rare, screening for narcolep­tic symptoms such as cataplexy, sleep-related hallucinations, and sleep paralysis can be helpful in the appropriate clinical scenario. Cataplexy is brief episodes of transient muscle weakness triggered by emotion, typ­ically positive emotion such as laughter. Sleep paralysis
Clinical Evaluation oftheObstructive Sleep Apnea Patient
71
6
. Fig. 6.1 Epworth
sleepiness scale (From: Johns MW.A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 1991;14(6):5400–545)
Epworth Sleepiness scale
Using the following scale, circle the most appropriate number for each situation.
0=would doze, less than once a month
1=slight chance of dozing
2=moderate chance of dozing
3=high chance of dozing
Situation Chance of Dozing
Sitting and reading 0 1 2 3
Watching TV 0 1 2 3
Sitting inactive in a public place (theatre, in a meeting) 0 1 2 3
As a passenger in a car for an hour without a break 0 1 2 3
Lying down to rest in an afternoon 0 1 2 3
Sitting and talking to someone 0 1 2 3
Sitting quietly after a lunch without alcohol 0 1 2 3
In a car, while stopped for a few minutes in traffic 0 1 2 3
8 numbers you have circled TOTAL = ______________________
From: Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness
scale. Sleep 1991;14(6):5400-545.
. Table 6.1 Important causes of excessive daytime
sleepiness to consider
Insufcient sleep
Obstructive sleep apnea
Central sleep apnea
Narcolepsy
Idiopathic hypersomnia
Circadian rhythm disorders
Restless legs syndrome
Medications
Drugs of abuse
Traumatic brain injury
Neurodegenerative disorders (e.g., dementia, Parkinson’s disease)
is a transient feeling of being awake but not being able to move, usually occurring while falling or waking up from sleep. Cataplexy is rarely seen outside a diagnosis of narcolepsy, but both sleep paralysis and sleep-related hallucinations can be seen in a variety of sleep disorders, including sleep apnea and sleep deprivation.
Certain medical diagnoses place patients at higher
risk for obstructive sleep apnea. These include pulmo­nary conditions such as chronic obstructive pulmonary disease and asthma as well as neurological conditions such as stroke or neuromuscular disorders. Patients with craniofacial disorders or midface hypoplasia, such as patients with cleft palate or Down’s syndrome are at higher risk of sleep-disordered breathing. Patients with cardiac diseases such as heart failure and cardiac arrhythmias (atrial brillation) have very high rates of both central and obstructive sleep apnea [7]. It will also be important to ask about any previous upper airway
72
R. K. Malhotra and R. Zeballos-Chavez
surgeries that the patient may have undergone for a pre­vious diagnosis of sleep apnea or airway difculties.
Patients may try to mask their symptoms of sleepi­ness by using caffeine or tobacco. While completing the social history, the provider should ask about any use of caffeine, tobacco, or other recreational drugs which can cause sleepiness during the day or insomnia at night. A history of smoking also puts the patient at risk for sleep apnea.
It is important to learn more about the patient’s employment, as certain occupations come with spe­cic regulations in regards to sleepiness and a diagno-
6
sis of obstructive sleep apnea. This typically includes occupations such as pilots or drivers with commercial driver’s licenses. Federal agencies have regulations in regards to adherence to therapy or possibly time off of work during evaluation for sleep apnea if there is perceived risk that the symptoms may put the worker or society at risk. It may also be helpful to ask if any family members have a history of obstructive sleep apnea (or symptoms suspicious for sleep apnea), as obstructive sleep apnea can run in families, especially if related to craniofacial or upper airway anatomical abnormalities.

6.3 Physical Examination

The clinical history as described above is critical in the evaluation of possible obstructive sleep apnea. There are key features on the physical examination that are also very helpful in the clinical evaluation. One of the most helpful objective measure is an elevated body mass index (BMI) or a nding of obesity. The higher the BMI, the higher the risk for obstructive sleep apnea (due to increase of fatty tissue in oropharyngeal structures including tongue). It is also important to measure the neck circumference as an increased neck circumfer­ence>17 inches in men and >16 inches in women are also considered risk factors and should be included in the initial clinical evaluation [8]. An elevated blood pres­sure (or a history of hypertension), abnormal respira­tory signs, or low oxygen saturations can be associated with sleep-disordered breathing.
A detailed upper airway and craniofacial examina­tion will be helpful in looking for characteristics that can predispose the patient to a narrow airway. The clinician should document the presence and size of tonsillar tis­sue as well as a gauge of how crowded the airway is upon visual inspection. One common method is the Mallampati classication which grades the airway from 1(least crowded) to 4(most crowded). The Mallampati classication or score was initially utilized by clinicians in determining ease of intubation but was later found to correlate with risk of obstructive sleep apnea. The score
is obtained by asking the patient while sitting to open their mouth and fully protrude their tongue (no phona­tion) and examining the airway. Mallampati 1 classica­tion is when you can see the soft palate, hard palate, uvula, and tonsillar pillars. A Mallampati 2 classica­tion is when you can view the other three structures, but not the tonsillar pillars. In a Mallampati class 3, only the soft and hard palate, and base of the uvula is visualized. In a Mallampati class 4, only the hard palate is noted, suggesting a crowded airway putting the patient at high­est risk for sleep apnea [9].
More detailed visualization of the upper airway can be performed by nasal endoscopy, though this is not routinely performed at most sleep centers unless surgical intervention is being considered. Craniofacial abnormalities such as retrognathia, micrognathia, mac­roglossia, scalloping of the tongue, or signicant overjet also place the patient at high risk for obstructive sleep apnea. Physical examination of nasopharynx should include evaluation for nasal obstruction from nasal tur­binate hypertrophy, septal deviation, nasal polyps, or other obstructing lesions.
Due to the common occurrence of cardiac disease and sleep apnea, and detailed cardiovascular examina­tion listening for murmurs, abnormal heartbeats, or signs of heart failure (lower extremity edema or elevated jugular venous distention) should be performed. An abnormal pulmonary exam may also suggest heart fail­ure (rales or crackles) or other pulmonary disorders (wheezing) putting the patient at risk for obstructive sleep apnea or other sleep-disordered breathing such as sleep-related hypoventilation or hypoxemia. Evaluating the distal extremities for any clubbing or cyanosis is also helpful to determine if there is any underlying cardio­vascular or pulmonary disease.
A detailed neurological examination, especially focusing on cranial nerve and motor function, can assist in the evaluation of obstructive sleep apnea. If patients have signicant motor weakness or signs of a central nervous system injury, this puts them at risk for not only obstructive sleep apnea, but also more complicated sleep-disordered breathing such as sleep-related hypoven­tilation or central sleep apnea which may require more complex evaluation and treatment.

6.4 Conclusion

Though objective testing is necessary to conrm a diag­nosis of obstructive sleep apnea, the history and physi­cal examination is key to a comprehensive evaluation of the patient with suspected sleep apnea. The history and physical not only helps guide which testing is necessary as the next step, but also evaluates for other possible causes for the patients presenting sleep symptoms.
Clinical Evaluation oftheObstructive Sleep Apnea Patient
73
6

References

1. American Academy of Sleep Medicine. International classica­tion of sleep disorders. 3rd ed. Darien, IL: American Academy of Sleep Medicine; 2014.
2. Young TB. Epidemiology of daytime sleepiness: denitions, symptomatology, and prevalence. J Clin Psychiatry. 2004;65(Suppl
16):12.
3. Kapur VK, Auckley DH, Chowdhuri S, Kuhlmann DC, Mehra R, Ramar K, Harrod CG.Clinical practice guideline for diagnostic testing for adult obstructive sleep apnea: an American Academy of sleep medicine clinical practice guideline. J Clin Sleep Med. 2017;13(3):479–504.
4. Chervin RD.Sleepiness, fatigue, tiredness, and lack of energy in obstructive sleep apnea. Chest. 2000;118(2):372–9.
5. Chervin RD, Archbold KH, Dillon JE, Panahi P, Pituch KJ, Dahl RE, Guilleminault C.Inattention, hyperactivity, and symptoms of sleep-disordered breathing. Pediatr March. 2002;109(3): 449–56.
6. Watson NF, Badr MS, Belenky G, Bliwise DL, Buxton OM, Buysse D, Dinges DF, Gangwisch J, Grandner MA, Kushida C, Malhotra RK, Martin JL, Patel SR, Quan SF, Tasali E.Joint con­sensus statement of the American Academy of sleep medicine and
Sleep Research Society on the recommended amount of sleep for a healthy adult: methodology and discussion. J Clin Sleep Med. 2015;11(8):931–52.
7. Mehra R, Benjamin EJ, Shahar E, Gottlieb DJ, Nawabit R, Kirchner HL, etal. Association of nocturnal arrhythmias with sleep-disordered breathing: the sleep heart health study. Am J Respir Crit Care Med. 2006;173(8):910–6.
8. Epstein LJ, Kristo D, Strollo PJ Jr, Friedman N, Malhotra A, Patil SP, Ramar K, Rogers R, Schwab RJ, Weaver EM, Weinstein MD.Clinical guideline for the evaluation, management and long­term care of obstructive sleep apnea in adults. J Clin Sleep Med. 2009;5(3):263.
9. Nuckton TJ, Glidden DV, Browner WS, Claman DM.Physical examination: mallampati socre as an independent predictor of obstructive sleep apnea. Sleep. 2006;29(7):903–8.
Further Reading
Kapur VK, Auckley DH, Chowdhuri S, Kuhlmann DC, Mehra R,
Ramar K, Harrod CG.Clinical practice guideline for diagnostic testing for adult obstructive sleep apnea: an American Academy of sleep medicine clinical practice guideline. J Clin Sleep Med. 2017;13(3):479–504.
Diagnostic Testing forObstructive Sleep Apnea
MeghnaP.Mansukhani, BhanuPrakashKolla, andKannanRamar
Contents
7.1 Background – 76
7.2 Diagnosis ofOSA – 76
7.2.1 History andExamination – 76
7.2.2 Screening Tools – 76
7.2.3 Diagnostic Tests – 77
7.2.4 Types ofSleep Studies – 77
7.2.5 Denition ofOSA – 77
7.2.6 Scoring ofRespiratory Events – 77
7.2.7 Clinical Guidelines – 78
75
7
7.3 Home Sleep Apnea Test (HSAT) – 78
7.3.1 Advantages – 78
7.3.2 Disadvantages – 78
7.3.3 Patient Selection – 78
7.3.4 Data Obtained – 79
7.3.5 Conduct andInterpretation ofTest – 79
7.3.6 Accuracy ofResults – 79
7.3.7 Discussion ofResults – 80
7.3.8 Recommended Follow-Up – 80
7.3.9 Clinical Outcomes – 80
7.3.10 Cost-Eectiveness – 80
7.3.11 Summary ofHSAT – 80
7.4 Polysomnography (PSG) – 80
7.4.1 Patient Selection – 80
7.4.2 Number andDuration ofTests – 81
7.4.3 Conduct andInterpretation oftheStudy – 81
7.4.4 Follow-Up – 81
7.4.5 Discussion ofResults – 81
7.4.6 Repeat Testing intheLong Term – 81
7.4.7 Summary ofPSG – 82
7.5 Conclusions – 82
Further Reading – 82
© Springer Nature Switzerland AG 2021 K. B. Kim et al. (eds.), Management of Obstructive Sleep Apnea, https://doi.org/10.1007/978-3-030-54146-0_7